These results indicate that rifampin induced drug metabolism, partially, by regulating UGT1A4, ADH6, CYP1A1, CYP2C19, CYP2C9 and CYP2E1. These results also signify that rifampin can influence the anti-angiogenesis and anti-tumour effects of drugs by regulating BIRC3, CAV1, CAV2, FN1, ITGA1 and THBS1. Previous reports support these findings, stating that UGT1A4 CYP1A1, CYP2C19, CYP2C9 and CYP2E1 are drug-metabolizing enzymes [34, 35], and ADH6 modulates the risk for drug dependence [35]. The gene discussed is CYP2C9; the disease is neoplasm.